Literature DB >> 35318442

HNF4A-AS1-encoded small peptide promotes self-renewal and aggressiveness of neuroblastoma stem cells via eEF1A1-repressed SMAD4 transactivation.

Huajie Song1, Jianqun Wang1, Xiaojing Wang2, Boling Yuan1, Dan Li1, Anpei Hu1, Yanhua Guo1, Shuang Cai3, Shikai Jin1, Yi Zhou3, Qilan Li1, Guo Chen1, Haiyang Gao4, Liduan Zheng5,6, Qiangsong Tong7,8.   

Abstract

Cancer stem cells play crucial roles in tumorigenesis and aggressiveness, while regulatory mechanisms in neuroblastoma (NB), a pediatric extracranial malignancy with highest incidence, are still unknown. Herein, a small 51-amino acid peptide (sPEP1) encoded by hepatocyte nuclear factor 4 alpha antisense RNA 1 (HNF4A-AS1) was identified in tumor tissues and cells, which facilitated self-renewal and aggressiveness of NB stem cells. MiRNA-409-5p interacted with HNF4A-AS1 to facilitate sPEP1 translation via recruiting eukaryotic translation initiation factor 3 subunit G, while sPEP1 repressed serum deprivation-induced senescence and promoted sphere formation, growth, or metastasis of NB stem cells. Mechanistically, sPEP1 directly interacted with eukaryotic translation elongation factor 1 alpha 1 (eEF1A1) to facilitate its binding to SMAD family member 4 (SMAD4), resulting in repression of SMAD4 transactivation and transcriptional upregulation of stem cell genes associated with tumor progression. Rescue experiments revealed that sPEP1 exerted oncogenic roles via facilitating physical interaction between eEF1A1 and SMAD4. Notably, knockdown of sPEP1 significantly repressed the self-renewal and metastasis of NB stem cells in vivo. High sPEP1 or eEF1A1 levels in clinical NB tissues were linked to poor patients' survival. These findings suggest that HNF4A-AS1-encoded sPEP1 promotes self-renewal and aggressive features of NB stem cells by eEF1A1-repressed SMAD4 transactivation.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35318442     DOI: 10.1038/s41388-022-02271-4

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  49 in total

1.  CD133 suppresses neuroblastoma cell differentiation via signal pathway modification.

Authors:  H Takenobu; O Shimozato; T Nakamura; H Ochiai; Y Yamaguchi; M Ohira; A Nakagawara; T Kamijo
Journal:  Oncogene       Date:  2010-09-06       Impact factor: 9.867

2.  Graded regulation of cellular quiescence depth between proliferation and senescence by a lysosomal dimmer switch.

Authors:  Kotaro Fujimaki; Ruoyan Li; Hengyu Chen; Kimiko Della Croce; Hao Helen Zhang; Jianhua Xing; Fan Bai; Guang Yao
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-21       Impact factor: 11.205

3.  Senescence-associated reprogramming promotes cancer stemness.

Authors:  Maja Milanovic; Dorothy N Y Fan; Dimitri Belenki; J Henry M Däbritz; Zhen Zhao; Yong Yu; Jan R Dörr; Lora Dimitrova; Dido Lenze; Ines A Monteiro Barbosa; Marco A Mendoza-Parra; Tamara Kanashova; Marlen Metzner; Katharina Pardon; Maurice Reimann; Andreas Trumpp; Bernd Dörken; Johannes Zuber; Hinrich Gronemeyer; Michael Hummel; Gunnar Dittmar; Soyoung Lee; Clemens A Schmitt
Journal:  Nature       Date:  2017-12-20       Impact factor: 49.962

4.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

Review 5.  Functional Classification and Experimental Dissection of Long Noncoding RNAs.

Authors:  Florian Kopp; Joshua T Mendell
Journal:  Cell       Date:  2018-01-25       Impact factor: 41.582

6.  Nestin is a potential mediator of malignancy in human neuroblastoma cells.

Authors:  Sharon K Thomas; Conrad A Messam; Barbara A Spengler; June L Biedler; Robert A Ross
Journal:  J Biol Chem       Date:  2004-04-26       Impact factor: 5.157

Review 7.  Advances in Risk Classification and Treatment Strategies for Neuroblastoma.

Authors:  Navin R Pinto; Mark A Applebaum; Samuel L Volchenboum; Katherine K Matthay; Wendy B London; Peter F Ambros; Akira Nakagawara; Frank Berthold; Gudrun Schleiermacher; Julie R Park; Dominique Valteau-Couanet; Andrew D J Pearson; Susan L Cohn
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

8.  Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell.

Authors:  Loen M Hansford; Amy E McKee; Libo Zhang; Rani E George; J Ted Gerstle; Paul S Thorner; Kristen M Smith; A Thomas Look; Herman Yeger; Freda D Miller; Meredith S Irwin; Carol J Thiele; David R Kaplan
Journal:  Cancer Res       Date:  2007-12-01       Impact factor: 12.701

9.  Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling.

Authors:  Vijayabaskar Pandian; Satishkumar Ramraj; Faizan H Khan; Tasfia Azim; Natarajan Aravindan
Journal:  Stem Cell Res Ther       Date:  2015-02-20       Impact factor: 6.832

10.  The small peptide world in long noncoding RNAs.

Authors:  Seo-Won Choi; Hyun-Woo Kim; Jin-Wu Nam
Journal:  Brief Bioinform       Date:  2019-09-27       Impact factor: 11.622

View more
  2 in total

1.  High eEF1A1 Protein Levels Mark Aggressive Prostate Cancers and the In Vitro Targeting of eEF1A1 Reveals the eEF1A1-actin Complex as a New Potential Target for Therapy.

Authors:  Alessandra Bosutti; Barbara Dapas; Gabriele Grassi; Rossana Bussani; Fabrizio Zanconati; Fabiola Giudici; Cristina Bottin; Nicola Pavan; Carlo Trombetta; Bruna Scaggiante
Journal:  Int J Mol Sci       Date:  2022-04-08       Impact factor: 6.208

Review 2.  Natural antisense transcripts as drug targets.

Authors:  Olga Khorkova; Jack Stahl; Aswathy Joji; Claude-Henry Volmar; Zane Zeier; Claes Wahlestedt
Journal:  Front Mol Biosci       Date:  2022-09-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.